P Harter
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V, Harter P. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2009; 21:370-5.
Nov 4, 2009A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
Nov 4, 2009Ann Oncol 2009; 21:370-5
du Bois A, Huober Jens, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt V L, Harter P
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
Harter P, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, Burges A, Hasenburg A, Hahmann M, Lueck H, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, du Bois A. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Annals of surgical oncology 2009; 16:1324-30.
May 1, 2009Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
May 1, 2009Annals of surgical oncology 2009; 16:1324-30
Harter P, Loibl S, Meier W, Huober Jens, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, Burges A, Hasenburg A, Hahmann M, Lueck H J, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, du Bois A
Non-enrolment of ovarian cancer patients in clinical trials: reasons and background
Harter P, Staehle A, Huober J, Schmalfeldt B, Gropp M, Wollschlaeger K, Burges A, Schade-Brittinger C, du Bois A, Pfisterer J. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1801-5.
Nov 1, 2005Non-enrolment of ovarian cancer patients in clinical trials: reasons and background
Nov 1, 2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:1801-5
Harter P, Staehle A, Huober Jens, Schmalfeldt B, Gropp M, Wollschlaeger K, Burges A, Schade-Brittinger C, du Bois A, Pfisterer J
The role of surgery in recurrent ovarian cancer
Pfisterer J, AGO Ovarian Committee, Bois A, Fink D, Huober J, Gropp M, Loibl S, Burges A, Hasenburg A, Hahmann M, Jackisch C, Richter B, Canzler U, Harter P, AGO Ovarian Cancer Study Group (AGO-OVAR). The role of surgery in recurrent ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005; 15 Suppl 3:195-8.
Jan 1, 2005The role of surgery in recurrent ovarian cancer
Jan 1, 2005International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005; 15 Suppl 3:195-8
Pfisterer J, AGO Ovarian Committee, Bois A, Fink D, Huober Jens, Gropp M, Loibl S, Burges A, Hasenburg A, Hahmann M, Jackisch C, Richter B, Canzler U, Harter P, AGO Ovarian Cancer Study Group (AGO-OVAR)